Stomatology Department, Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai City, China.
Otorhinolaryngology Department, Yantai Fushan People's Hospital, Yantai City, China.
Cancer Med. 2018 Oct;7(10):5187-5193. doi: 10.1002/cam4.1781. Epub 2018 Sep 21.
Laryngeal cancer is a common cancer occurred in the head and neck. Irradiation sensitivity is a problem affecting the treatment of laryngeal cancer. Tanshinone IIA has been reported to play an important role in treating multiple diseases; yet, whether Tanshinone IIA can be an irradiation sensitizer has not been reported. Clonogenic assay, annexin-V/propidium iodide double-staining assay, and Cell Counting Kit-8 assay were performed to detect cell survival, proliferation, apoptosis, and viability. Mouse laryngeal cancer xenograft model was established and subjected to tumor size analysis. Tanshinone IIA treatment increased the irradiation sensitivity of laryngeal cancer cells by reducing cell survival, viability and proliferation, and increasing cell apoptosis. Tanshinone IIA treatment increased the survival period of mice in the in vivo laryngeal cancer model, evidenced by decreased growth and weight of tumors, which was possibly mediated through the JNK pathway. Tanshinone IIA increases the sensitivity to irradiation in laryngeal cancer cells and in vivo laryngeal cancer model, suggesting that Tanshinone IIA can be a therapeutic antitumor agent for treating laryngeal cancer.
喉癌是一种常见的头颈部癌症。放射敏感性是影响喉癌治疗的一个问题。丹参酮 IIA 已被报道在治疗多种疾病中发挥重要作用；然而，丹参酮 IIA 是否可以作为放射增敏剂尚未有报道。采用集落形成实验、Annexin-V/碘化丙啶双染实验和细胞计数试剂盒-8 实验检测细胞存活、增殖、凋亡和活力。建立了小鼠喉癌异种移植模型，并进行肿瘤大小分析。丹参酮 IIA 通过降低细胞存活率、活力和增殖，增加细胞凋亡，增加了喉癌细胞对放疗的敏感性。丹参酮 IIA 治疗增加了体内喉癌模型中小鼠的生存期，表现为肿瘤生长和体重减轻，这可能是通过 JNK 通路介导的。丹参酮 IIA 增加了喉癌细胞和体内喉癌模型对放疗的敏感性，提示丹参酮 IIA 可以作为治疗喉癌的抗肿瘤治疗药物。
